Florbetaben for Imaging of Vascular Amyloid

What this study is about

The Primary Objective is to determine if a new nuclear tracer (named 18F-Florbetaben) used with nuclear imaging (PET imaging) can detect inflamed plaque in patients with recent ACS or stroke/TIA.

Who can join (things the study team will check)

✅ You may be able to join if…

• suffered a recent cardiovascular event (30-120 days post ACS (i.e. STEMI or NSTEMI) or TIA/stroke with ipsilateral large vessel atherosclerotic disease confirmed on US, CT or MRI;
• stable symptoms and hemodynamics;
• age >/= 18 years;
• given informed consent.

🚫 You may not be able to join if…

• a recent CV event likely to have been embolic in the opinion of the neurologist or cardiologist;
• severe LV dysfunction (EF<30%);
• severe valve disease requiring intervention;
• decompensated heart failure;
• pregnancy (all women of child bearing potential will have a negative BHCG test;
• breastfeeding;
• women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception;.
• unable to give informed consent;.
• Florbetaben allergy;
• glomerular filtration rate (GFR) <50 ml/min/1.72m2 Exclusion for CTA portion of the protocol: Patients with dye allergy, or those with GFR <60, will not undergo CTA but will have PET/CT.

Where this trial is running

• University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Who to contact

Kevin E Boczar, MD · 6132821835 · kboczar@ottawaheart.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06091319.